All Updates

All Updates

icon
Filter
Funding
Nexo Therapeutics raises USD 60 million in Series A funding; launches from stealth
Precision Medicine
Jul 26, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 26, 2023

Nexo Therapeutics raises USD 60 million in Series A funding; launches from stealth

Funding

  • Drug discovery and developer Nexo therapeutics has launched out of stealth with USD 60 million in Series A funding. The round was led by Versant Ventures, with participation from New Enterprise Associates and Cormorant Asset Management.

  • The funds will be used to develop its platform. 

  • Nexo Therapeutics is a small molecule oncology company focusing on discovering and developing drugs for cancer patients who lack effective therapies. Its platform addresses challenges in ligand discovery and optimization by combining a chemistry engine (CODON) and a chemical biology capability (INFINI-T). This allows Nexo to pursue challenging, high-value targets and expedite drug candidates' development.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.